PCLO.F Stock Overview
Together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
PharmaCielo Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.11 |
52 Week High | CA$0.22 |
52 Week Low | CA$0.079 |
Beta | 2.44 |
11 Month Change | -20.70% |
3 Month Change | -24.76% |
1 Year Change | -25.46% |
33 Year Change | -90.48% |
5 Year Change | -97.79% |
Change since IPO | -98.40% |
Recent News & Updates
Recent updates
Shareholder Returns
PCLO.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -25.5% | -0.4% | 0.04% |
1Y | -25.5% | 17.0% | 20.7% |
Return vs Industry: PCLO.F underperformed the US Pharmaceuticals industry which returned 17% over the past year.
Return vs Market: PCLO.F underperformed the US Market which returned 20.7% over the past year.
Price Volatility
PCLO.F volatility | |
---|---|
PCLO.F Average Weekly Movement | 40.8% |
Pharmaceuticals Industry Average Movement | 9.9% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: PCLO.F's share price has been volatile over the past 3 months.
Volatility Over Time: PCLO.F's weekly volatility has increased from 24% to 41% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Marc Lustig | www.pharmacielo.com |
PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia.
PharmaCielo Ltd. Fundamentals Summary
PCLO.F fundamental statistics | |
---|---|
Market cap | US$19.23m |
Earnings (TTM) | -US$9.37m |
Revenue (TTM) | US$2.05m |
9.4x
P/S Ratio-2.1x
P/E RatioIs PCLO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PCLO.F income statement (TTM) | |
---|---|
Revenue | CA$2.81m |
Cost of Revenue | CA$3.55m |
Gross Profit | -CA$737.25k |
Other Expenses | CA$12.08m |
Earnings | -CA$12.82m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.076 |
Gross Margin | -26.23% |
Net Profit Margin | -456.04% |
Debt/Equity Ratio | 599.3% |
How did PCLO.F perform over the long term?
See historical performance and comparison